13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 10 of 3,340 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04150549 (ClinicalTrials.gov)	June 2023	11/10/2019	FMT for MS Patients	Fecal Microbial Transplantation for Relapsing Multiple SclerosisPatients - a Placebo-controlled, Dou ...	Multiple Sclerosis	Biological: Fecal Microbial Transplants	Lawson Health Research Institute	NULL	Not yet recruiting	18 Years	55 Years	All	34	Phase 2	NULL
2	NCT05179577 (ClinicalTrials.gov)	June 2023	12/11/2021	A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multip ...	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Ef ...	Spasticity	Drug: Arbaclofen;Drug: Placebo	RVL Pharmaceuticals, Inc.	NULL	Not yet recruiting	18 Years	65 Years	All	442	Phase 3	NULL
3	NCT05658484 (ClinicalTrials.gov)	April 13, 2023	12/12/2022	A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis(RMS) Participants in Chi ...	A Multicenter, Postmarketing Study of Dimethyl Fumarate (Tecfidera; BG00012) in Relapsing Forms of M ...	Multiple Sclerosis	Drug: Dimethyl fumarate	Biogen	NULL	Not yet recruiting	18 Years	65 Years	All	60	Phase 4	NULL
4	NCT05754593 (ClinicalTrials.gov)	April 2023	21/2/2023	Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis(MS), Compared to a Control Grou ...	Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis, Compared to a Control Group	Multiple Sclerosis	Biological: Anti-Mullerian hormone (AMH) level;Other: Antral follicle count (AFC);Other: Clinical as ...	University Hospital, Bordeaux	NULL	Not yet recruiting	25 Years	35 Years	Female	160	N/A	France
5	NCT05359653 (ClinicalTrials.gov)	March 22, 2023	28/4/2022	Assessing Changes in Multi-parametric MRI in MSPatients Taking Clemastine Fumarate as a Myelin Repai ...	A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Mul ...	Multiple Sclerosis(MS);Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Primary Progressi ...	Drug: Clemastine Fumarate;Drug: Placebo	University of California, San Francisco	United States Department of Defense	Not yet recruiting	18 Years	55 Years	All	74	Phase 1/Phase 2	United States
6	NCT05740722 (ClinicalTrials.gov)	March 1, 2023	30/1/2023	Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis	Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Tri ...	Multiple Sclerosis;Progressive Multiple Sclerosis	Dietary Supplement: Nicotinamid riboside;Dietary Supplement: Placebo	Haukeland University Hospital	NULL	Not yet recruiting	18 Years	65 Years	All	300	Phase 2	Norway
7	NCT05199688 (ClinicalTrials.gov)	February 28, 2023	3/12/2021	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satral ...	A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Saf ...	Neuromyelitis Optica Spectrum Disorder;NMOSD	Drug: Satralizumab	Hoffmann-La Roche	NULL	Recruiting	2 Years	11 Years	All	8	Phase 3	France;Poland;United Kingdom;Argentina;Italy;Mexico;Ukraine;United States
8	NCT05758831 (ClinicalTrials.gov)	February 28, 2023	17/2/2023	RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.	A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsin ...	Multiple Sclerosis;Relapsing-remitting Multiple Sclerosis	Drug: Perfusion of treatment Rituximab;Drug: Perfusion of treatment Ocrelizumab	Rennes University Hospital	NULL	Not yet recruiting	18 Years	55 Years	All	386	Phase 3	France
9	NCT05208840 (ClinicalTrials.gov)	February 14, 2023	12/1/2022	A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis	Open-Label Multicenter Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation I ...	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	65 Years	All	50	Phase 4	Russian Federation
10	NCT05539729 (ClinicalTrials.gov)	February 8, 2023	12/9/2022	Vancomycin Study in Multiple Sclerosis (MS)	Impact of Vancomycin on the Gut Microbiome and Immune Function in Multiple Sclerosis	Multiple Sclerosis	Drug: Vancomycin;Drug: Placebo	Icahn School of Medicine at Mount Sinai	Doris Duke Charitable Foundation	Recruiting	18 Years	45 Years	All	40	Phase 1	United States

First Previous1 2 3 4 5…334Next Last